Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Muscle Regeneration: ALKAHEST
Test period: January 2023 – March 2024 Investigators: Alkahest: Benson Lu, PhD & Annette Tennstaedt, PhD Myologica: Ramzi Khairallah, PhD Lay abstract Muscle Regeneration Projects We don’t have a cure…
Read MoreFSHD-Like Mini-PIG MRI Project
Test period: The bulk of this project will be completed in 2024. Investigator: Peter Jones, PhD (University of Nevada, Reno) Lay abstract The Peter and Takako Jones Lab is in…
Read MoreEffect of Matrix Bound Nanovesicles in a rodent model of FSHD: Histomorphologic Analysis
Test period: August 1, 2023 to January 31, 2024 Investigators: George Hussey, PhD and Stephen F. Badylak, DVM, PhD, MD The proposed studies will evaluate the immune and myogenic cell…
Read MoreMatrix Bound Vesicles for the Treatment of DUX4-mediated Muscle Pathology
Investigators: Collaborative study between Dr. Michael Kyba (UMN) and Dr. Stephen Badylak (UPMC) This study will investigate the effects of treating muscle with GMP produced matrix-bound vesicles (MBVs) in the iDUX4pA/HSA…
Read MorePhenotypic characterization of FSHD-like FLExDUX4 minipigs
Investigator: Peter L. Jones, PhD, University of Nevada, Reno School of Medicine All forms of FSHD are caused by misexpression of DUX4 (double homeobox protein 4) in skeletal muscles; thus, the…
Read MoreMatrix Bound Nanovesicles (MBV) as a Therapy for FSHD
Investigator: Dr. George Hussey, University of Pittsburgh Regenerative Medicine provides an alternative FSHD treatment strategy for promoting new tissue growth using Extracellular Matrix (ECM) bioscaffolds. ECM bioscaffolds serve as a biochemical…
Read More